vs
CuriosityStream Inc.（CURI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是CuriosityStream Inc.的1.6倍（$30.3M vs $19.2M），CuriosityStream Inc.净利率更高（-19.7% vs -221.3%，领先201.6%），REGENXBIO Inc.同比增速更快（43.0% vs 35.8%），CuriosityStream Inc.自由现金流更多（$3.9M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 26.5%）
CuriosityStream是来自美国的流媒体订阅点播服务商，主打纪实类影视内容，涵盖纪录片长片、系列纪实节目与电视栏目。除了品牌同名的视频点播订阅服务外，该公司还开设了Curiosity纪实线性电视频道，目前已接入FuboTV、Roku频道等多个平台。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CURI vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$19.2M
营收增速更快
RGNX
高出7.2%
35.8%
净利率更高
CURI
高出201.6%
-221.3%
自由现金流更多
CURI
多$56.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
26.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.2M | $30.3M |
| 净利润 | $-3.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -17.6% | -190.0% |
| 净利率 | -19.7% | -221.3% |
| 营收同比 | 35.8% | 43.0% |
| 净利润同比 | -34.6% | -31.2% |
| 每股收益（稀释后） | $-0.07 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CURIRGNX
| Q4 25 | $19.2M | $30.3M | ||
| Q3 25 | $18.4M | $29.7M | ||
| Q2 25 | $19.0M | $21.4M | ||
| Q1 25 | $15.1M | $89.0M | ||
| Q4 24 | $14.1M | $21.2M | ||
| Q3 24 | $12.6M | $24.2M | ||
| Q2 24 | $12.4M | $22.3M | ||
| Q1 24 | $12.0M | $15.6M |
净利润CURIRGNX
| Q4 25 | $-3.8M | $-67.1M | ||
| Q3 25 | $-3.7M | $-61.9M | ||
| Q2 25 | $784.0K | $-70.9M | ||
| Q1 25 | $319.0K | $6.1M | ||
| Q4 24 | $-2.8M | $-51.2M | ||
| Q3 24 | $-3.1M | $-59.6M | ||
| Q2 24 | $-2.0M | $-53.0M | ||
| Q1 24 | $-5.0M | $-63.3M |
毛利率CURIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CURIRGNX
| Q4 25 | -17.6% | -190.0% | ||
| Q3 25 | -24.5% | -176.3% | ||
| Q2 25 | 2.5% | -296.3% | ||
| Q1 25 | 0.5% | 13.6% | ||
| Q4 24 | -27.4% | -242.1% | ||
| Q3 24 | -25.8% | -256.6% | ||
| Q2 24 | -20.6% | -251.3% | ||
| Q1 24 | -30.4% | -408.8% |
净利率CURIRGNX
| Q4 25 | -19.7% | -221.3% | ||
| Q3 25 | -20.4% | -208.3% | ||
| Q2 25 | 4.1% | -331.8% | ||
| Q1 25 | 2.1% | 6.8% | ||
| Q4 24 | -19.9% | -241.3% | ||
| Q3 24 | -24.3% | -246.3% | ||
| Q2 24 | -16.4% | -237.7% | ||
| Q1 24 | -42.0% | -405.4% |
每股收益（稀释后）CURIRGNX
| Q4 25 | $-0.07 | $-1.30 | ||
| Q3 25 | $-0.06 | $-1.20 | ||
| Q2 25 | $0.01 | $-1.38 | ||
| Q1 25 | $0.01 | $0.12 | ||
| Q4 24 | $-0.05 | $-0.99 | ||
| Q3 24 | $-0.06 | $-1.17 | ||
| Q2 24 | $-0.04 | $-1.05 | ||
| Q1 24 | $-0.09 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.3M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $41.5M | $102.7M |
| 总资产 | $75.7M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CURIRGNX
| Q4 25 | $27.3M | $230.1M | ||
| Q3 25 | $27.8M | $274.2M | ||
| Q2 25 | $28.1M | $323.3M | ||
| Q1 25 | $33.4M | $267.9M | ||
| Q4 24 | $32.1M | $234.7M | ||
| Q3 24 | $33.2M | $255.5M | ||
| Q2 24 | $39.5M | $290.4M | ||
| Q1 24 | $38.8M | $338.7M |
股东权益CURIRGNX
| Q4 25 | $41.5M | $102.7M | ||
| Q3 25 | $47.2M | $161.5M | ||
| Q2 25 | $49.8M | $213.7M | ||
| Q1 25 | $58.1M | $274.2M | ||
| Q4 24 | $57.8M | $259.7M | ||
| Q3 24 | $62.2M | $301.4M | ||
| Q2 24 | $64.8M | $348.3M | ||
| Q1 24 | $67.0M | $390.7M |
总资产CURIRGNX
| Q4 25 | $75.7M | $453.0M | ||
| Q3 25 | $74.7M | $525.2M | ||
| Q2 25 | $78.7M | $581.0M | ||
| Q1 25 | $85.3M | $490.9M | ||
| Q4 24 | $86.2M | $466.0M | ||
| Q3 24 | $87.6M | $519.1M | ||
| Q2 24 | $90.9M | $569.4M | ||
| Q1 24 | $94.6M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $3.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | 20.5% | -174.0% |
| 资本支出强度资本支出/营收 | 0.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CURIRGNX
| Q4 25 | $4.0M | $-52.3M | ||
| Q3 25 | $4.4M | $-56.0M | ||
| Q2 25 | $2.8M | $-49.3M | ||
| Q1 25 | $1.9M | $33.6M | ||
| Q4 24 | $3.0M | $-31.6M | ||
| Q3 24 | $2.3M | $-40.5M | ||
| Q2 24 | $2.2M | $-45.5M | ||
| Q1 24 | $666.0K | $-55.5M |
自由现金流CURIRGNX
| Q4 25 | $3.9M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $1.8M | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率CURIRGNX
| Q4 25 | 20.5% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | 12.2% | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度CURIRGNX
| Q4 25 | 0.1% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.5% | 1.2% | ||
| Q4 24 | 0.0% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率CURIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 6.03× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CURI
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
